Gilead Sciences, Inc.

Cv Therapeutics, Inc.

Incarda Therapeutics, Inc.

Gilead Palo Alto, Inc.

University of Florida Research Foundation, Incorporated

Luiz Belardinelli

Jeff A Zablocki

Dewan Zeng

Venkata Poornapragnacharyulu Palle

Elfatih O Elzein

Carlos A Schuler

Zhenhai Gao

Brent K Blackburn

Rangachari Narasimhan

Mitchell Rosner

John Shryock

Charles Antzelevitch

Prashanti Madhavapeddi

Alexander Burashnikov

Hongyan Zhong

Michael Laird Hurrey

Arvinder Dhalla

Toufigh Gordi

Ann Walls Olmsted

Vaibhav Varkhedkar

Maria B Grant

Hsiao Lieu

Michael R Blackburn

Brent Blackburn

Suya Yang

Hunter Campbell Gillies

Hsiao Dee Lieu

Faquan Liang

Ramin Farzaneh-Far

Sridharan Rajamani

Venkata P Palle

Miguel Guzman

Hsiao D Lieu

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.

Antiarrhythmic formulation

Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective &#x3b2;1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective &#x3b2;1 adrenergic receptor blocker and class I antiarrhythmic agent.

Method to slow ventricular rate

Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.

Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation

Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as AA-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.

2-(N-pyrazolo)adenosines with application as adenosine Areceptor agonists

Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Compositions and methods of treating pulmonary hypertension

A myocardial imaging method that is accomplished by administering one or more adenosine Aadenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one Areceptor agonist, at least one liquid carrier, and at least one co-solvent.

Myocardial perfusion imaging methods and compositions

The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.

Methods of myocardial perfusion imaging

Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker.

Compound and methods for treating long QT syndrome

The present disclosure relates to a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy.

Methods of treating hypertrophic cardiomyopathy

The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Method of treating atrial fibrillation

The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for Aadenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. 

Growing community of inventors

Palo Alto, CA, United States of America

Luiz Belardinelli